ES2602453T3 - Inmunoterapia antitumoral - Google Patents

Inmunoterapia antitumoral Download PDF

Info

Publication number
ES2602453T3
ES2602453T3 ES09776746.1T ES09776746T ES2602453T3 ES 2602453 T3 ES2602453 T3 ES 2602453T3 ES 09776746 T ES09776746 T ES 09776746T ES 2602453 T3 ES2602453 T3 ES 2602453T3
Authority
ES
Spain
Prior art keywords
seq
adjuvant
restricted
tumor immunotherapy
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09776746.1T
Other languages
English (en)
Inventor
Gilberto Filaci
Francesco Indiveri
Paolo Traverso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mediolanum Farmaceutici SpA
Original Assignee
Mediolanum Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediolanum Farmaceutici SpA filed Critical Mediolanum Farmaceutici SpA
Application granted granted Critical
Publication of ES2602453T3 publication Critical patent/ES2602453T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una composición de 4 péptidos de una telomerasa de mamífero, que comprende: (i) un péptido restringido por el HLA de clase I y (ii) tres péptidos restringidos por el HLA de clase II en combinación con un adyuvante, en donde: (a) dicho péptido restringido por el HLA de clase I es (SEQ ID n.º 1), (b) dichos tres péptidos restringidos por el HLA de clase II son, respectivamente, (SEQ ID n.º 2), (SEQ ID n.º 3) y (SEQ ID n.º 4), (c) dicho adyuvante es capaz de interaccionar con los receptores de tipo toll (TLR), y en donde dicho adyuvante es imiquimod.

Description

imagen1
imagen2
imagen3
imagen4

Claims (1)

  1. imagen1
ES09776746.1T 2008-06-16 2009-06-16 Inmunoterapia antitumoral Active ES2602453T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6177808P 2008-06-16 2008-06-16
US61778P 2008-06-16
PCT/EP2009/004337 WO2010003520A2 (en) 2008-06-16 2009-06-16 Anti-tumor immunotherapy

Publications (1)

Publication Number Publication Date
ES2602453T3 true ES2602453T3 (es) 2017-02-21

Family

ID=41507473

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09776746.1T Active ES2602453T3 (es) 2008-06-16 2009-06-16 Inmunoterapia antitumoral

Country Status (14)

Country Link
US (1) US8828403B2 (es)
EP (1) EP2310044B1 (es)
JP (1) JP5787752B2 (es)
CA (1) CA2727388C (es)
CY (1) CY1118215T1 (es)
DK (1) DK2310044T3 (es)
ES (1) ES2602453T3 (es)
HR (1) HRP20161434T1 (es)
HU (1) HUE030984T2 (es)
LT (1) LT2310044T (es)
PL (1) PL2310044T3 (es)
PT (1) PT2310044T (es)
SI (1) SI2310044T1 (es)
WO (1) WO2010003520A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2581800C2 (ru) 2010-02-16 2016-04-20 Ультимовакс Ас Полипептиды
WO2013169060A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 패혈증 예방 또는 치료용 조성물
CN108949717B (zh) * 2012-05-11 2023-06-20 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
KR102201430B1 (ko) * 2012-09-19 2021-01-12 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
TWI655204B (zh) * 2012-09-19 2019-04-01 韓商傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
KR102093093B1 (ko) * 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
ES2716870T3 (es) * 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
CA2912557A1 (en) 2013-06-07 2014-12-11 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
KR102166545B1 (ko) * 2013-06-21 2020-10-16 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
KR102204476B1 (ko) * 2013-08-14 2021-01-19 주식회사 젬백스앤카엘 다발성 경화증 치료 및 예방용 조성물
KR101691479B1 (ko) 2013-10-23 2017-01-02 주식회사 젬백스앤카엘 전립선 비대증 치료 및 예방용 조성물
WO2015072750A1 (ko) * 2013-11-12 2015-05-21 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
KR102494803B1 (ko) * 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
CN106456697B (zh) 2014-04-11 2019-12-17 珍白斯凯尔有限公司 具有纤维化抑制活性的肽和含有其的组合物
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
EP3441082B1 (en) 2016-04-07 2023-06-21 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
WO2003038047A2 (en) * 2001-10-29 2003-05-08 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
ITMI20032121A1 (it) * 2003-11-04 2005-05-05 Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm Procedimento per la preparazione di imiquimod e suoi intermedi

Also Published As

Publication number Publication date
HRP20161434T1 (hr) 2017-02-24
US8828403B2 (en) 2014-09-09
PT2310044T (pt) 2016-11-18
CY1118215T1 (el) 2017-06-28
JP2011524390A (ja) 2011-09-01
HUE030984T2 (en) 2017-06-28
CA2727388A1 (en) 2010-01-14
LT2310044T (lt) 2016-12-27
DK2310044T3 (en) 2016-12-12
PL2310044T3 (pl) 2017-04-28
US20110135692A1 (en) 2011-06-09
CA2727388C (en) 2017-08-29
WO2010003520A3 (en) 2010-07-15
EP2310044B1 (en) 2016-08-24
WO2010003520A2 (en) 2010-01-14
SI2310044T1 (sl) 2017-03-31
JP5787752B2 (ja) 2015-09-30
EP2310044A2 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
ES2602453T3 (es) Inmunoterapia antitumoral
ES2621211T3 (es) Composiciones inmunogénicas que comprenden polipéptidos de mycobacterium tuberculosis y fusiones de los mismos
CL2019003310A1 (es) Nuevos péptidos (seq id no:1) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer. (divisional solicitud 201800124)
CL2008001491A1 (es) Composicion liofilizada que comprende uno o mas antigenos y un agonista del receptor de tipo toll 9 (tlr9); y procedimiento de preparacion.
GB201009273D0 (en) Novel vaccine
CU24502B1 (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
DOP2015000050A (es) Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida
CL2017001819A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
ES2723773T3 (es) Luciferasas derivadas de Oplophorus, nuevos sustratos de celenterazina y procedimientos de uso
TW201614896A (en) Organic electroluminescent element
TWD160581S (zh) 發光裝置元件之部分（二）
AR076106A1 (es) Anticuerpos anti-cd40 y usos de los mismos
RS54182B1 (en) NEW IMMUNOTHERAPY AGAINST MULTIPLE TUMORS, INCLUDING GASTROINTESTINAL CARCIN AND CARIN CANCER
UY31361A1 (es) Vacunas y componentes para inhibir celulas microbianas
ECSP10010438A (es) ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS Y METODOS DE USO
CR20110619A (es) Produccion recombinante de peptidos
GB201209536D0 (en) Light emitting composition and device
UY3743Q (es) Aspiradora de mano (portatil)
FR2973387B1 (fr) Composition polyamide de forte conductivite thermique
CL2019002878A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer.
DOP2020000113A (es) Oligonucleótidos inmunoestimulantes
AR056591A1 (es) Polipeptidos ligandos para receptor 4 simil toll (tlr4)
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso
EP2565955A3 (en) Oled tile for illumination